There are currently 545 clinical trials in Lexington, Kentucky looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Kentucky, University of Kentucky/Markey Cancer Center, Saint Joseph Hospital East and Baptist Health Lexington. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Accelerated Transcranial Magnetic Stimulation (TMS) for Smoking Cessation in People Living With HIV/AIDS (PLWHA)
NCT05295953
Recruiting
To demonstrate whether four sessions of TBS improves attentional bias and craving in PLWHA smokers compared to four sessions of sham stimulation. We hypothesize 4 sessions of TBS to the left DLPFC will significantly improve attentional bias and craving for smoking cues compared to neutral cues in a population of subjects who are smokers with HIV/AIDS compared to sham stimulation.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
01/11/2024
Locations: 245 Fountain Court, Lexington, Kentucky +1 locations
Conditions: Hiv, Tobacco Smoking
Register for Updates
NM Balance Regulation With ULLS and Loss of Sleep
NCT05956964
Recruiting
The goal of this trial is to learn about how restricted sleep and not bearing weight on the leg affects muscle strength and posture control. Participants will walk exclusively on one leg, sleep at differing intervals, and complete posture tests, muscle strength tests, and muscle imaging. Researchers will compare adequate sleep and restricted sleep to see if muscle strength and posture are affected.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
01/11/2024
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Muscle Weakness, Quadriceps Muscle Atrophy, Sleep Disturbance
Register for Updates
Neurobehavioral Mechanisms of Choice in Opioid Use Disorder
NCT03958474
Recruiting
The objective of this protocol is to use probabilistic reinforcement learning choice tasks and magnetic resonance neuroimaging to demonstrate the impact of problematic opioid use and opioid withdrawal on dynamic decision-making and reveal the neurobehavioral and neurobiological processes underlying abnormal task performance. A second objective is to identify an appropriate dose of intravenous remifentanil for subsequent studies in physically dependent individuals with opioid use disorder.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
01/10/2024
Locations: Laboratory of Human Behavioral Pharmacology, Lexington, Kentucky
Conditions: Opioid Use Disorder
Register for Updates
C-Brace Prospective Registry
NCT04640584
Recruiting
To gather prospective safety and effectiveness data for the C-Brace System following the standard of care.
Gender:
All
Ages:
All
Trial Updated:
01/09/2024
Locations: Kenney Orthopedics - Lexington, Lexington, Kentucky
Conditions: Pareses, Lower Extremity
Register for Updates
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376
Recruiting
This phase III trial compares the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. Chemotherapy drugs, such as lomustine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy photons to kill tumor cells and s... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
01/09/2024
Locations: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
Conditions: Glioblastoma, Gliosarcoma
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia
NCT05778188
Recruiting
Hypoxic-ischemic encephalopathy (HIE) affects approximately 4,000 to 12,000 persons annually in the United States. Mortality from HIE has been reported up to 60%, with at least 25% of survivors left with significant neurocognitive disability. Despite this vital unmet medical need, no pharmacological adjunct or alternative therapy has proven beneficial in improving outcomes in neonatal HIE. RLS-0071 is a novel peptide being developed for the treatment of neonatal HIE. This study is designed to e... Read More
Gender:
All
Ages:
10 hours and below
Trial Updated:
01/08/2024
Locations: Study Site 012, Lexington, Kentucky
Conditions: Hypoxic-Ischemic Encephalopathy
Register for Updates
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
NCT05446298
Recruiting
This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/05/2024
Locations: Baptist Health Lexington, 407, Lexington, Kentucky
Conditions: Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Register for Updates
Phase 1 Dose Escalation of ArtemiCoffee
NCT04805333
Recruiting
This is a phase I dose-escalation study of Artemisia annua (Aa) in patients with advanced ovarian cancer who have completed front-line chemotherapy with carboplatin and paclitaxel. The primary objective of this study is to determine the recommended phase II dose (RP2D) of Artemisia annua.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/05/2024
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Ovarian Cancer
Register for Updates
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
NCT02915198
Recruiting
This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in patients who have pre-diabetes and heart or blood vessel problems.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/05/2024
Locations: Lexington VA Medical Center, Lexington, KY, Lexington, Kentucky
Conditions: Prediabetic State, Atherosclerosis, Metformin
Register for Updates
Hepatitis C Treatment in Probation and Parole Office
NCT05413785
Recruiting
This prospective cohort study compares aims to determine the efficacy and effectiveness of telemedicine-supported on-site linkage to care and treatment in a community probation and parole office (P&P office) setting and compare the results with a historic control with referral to care. Research participants will be followed in the P&P office when they report to their officer during regularly scheduled appointments. Participants will receive treatment without having to travel to a specialist's of... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
01/05/2024
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Hepatitis C, HCV
Register for Updates
Changes in Biomarker of Exposure in Adults Who Smoke Cigarettes Switching From Cigarettes to Heated Tobacco Products
NCT06179290
Recruiting
The purpose of the study is to evaluate changes in biomarkers of exposure (BoE) to harmful and potentially harmful constituents (HPHCs) in adult smokers who completely switch to Ploom heated tobacco products (HTPs) compared to those who continue to smoke usual brand combustible cigarettes (UBCC).
Gender:
All
Ages:
Between 22 years and 65 years
Trial Updated:
01/04/2024
Locations: Alliance for Multispecialty Research, LLC, Lexington, Kentucky
Conditions: Tobacco Use
Register for Updates
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
NCT05403541
Recruiting
The purpose of this 4-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 340 mg SC QW or placebo. The primary efficacy endpoint will be assessed by change in the myasthenia gravis activities of daily living (MG- ADL) score in acetylcholine receptor antibody seropositive (AChRAb+) participants. In Period 2, participants previo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/02/2024
Locations: Site Number -1003, Lexington, Kentucky
Conditions: Generalized Myasthenia Gravis
Register for Updates